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Background: CF associated liver disease (CFLD) mainly develops in early childhood and occurs in up to 30% of CF patients including features of steatosis, fibrosis and cholestasis. We aimed at characterizing liver disease in adult patients with CF after lung transplantation (LuTx). Methods: Consecutive patients admitted to our outpatient clinic received ultrasound, fibroscan, MRI/MRCP as well as testing of liver function tests, lipids and vitamin D. Liver diseases of other origins were excluded. Results: 36 patients (median age 30 y, IQR 25−38 y; 42% male) were included in the study. Median time since LuTx was 4.5 y (IQR: 2.3−8.3 y). Elevated AP/GGT were found in 33%, elevated ALT/AST levels in 28% of patients. In 43% (12/23) of patients steatosis and in 18% (4/23) either fibrosis or liver cirrhosis was diagnosed by ultrasound. In 39% (7/18) of patients MRI/MRCP revealed cholangiectasia, and delayed excretion of contrast medium in 20% (3/15). Fibroscan proved cirrhosis in 2 patients, whereas in all other patients fibrosis 0 to 1 was detected. No association of liver function tests and results of imaging was found. Steatosis was significantly associated with hypertriglyceridemia (p < 0.05), but not with hypercholesterolemia. Vitamin D levels in general were low. However, neither an association of vitamin D, nor gender or BMI with liver disease was evident. Conclusion: About 40% of post transplant patients show bile duct alterations suggesting presence of CFLD. Hepatic steatosis associated with hypertriglyceridemia is a common finding in adult CF patients after LuTx. Liver function tests seem to be a weak parameter for monitoring liver disease in CF patients. The aim of the study was to evaluate the relationship between the genotype, clinical picture and features of liver damage in infants with cystic fibrosis (CF) diagnosed during newborn screening.
Patients and Methods:
The analysis involved 42 children, aged from 2 to 6 months, in whom CF was diagnosed on the basis of screening tests. The analysis included: genotype, birth weight, Apgar score, clinical symptoms, parameters of pancreatic exocrine function, markers of liver damage and cholestasis, and abdominal ultrasound abnormalities. The obtained results were statistically analysed. Results: The most common mutations of CFTR gene observed in infants with diagnosed CF were: mutation delF508 − 36/42 − 85.7% [homozygotes delF508/delF508 − 13/42 − 30.9% − heterozygotes delF508/other mutations 23/42 − 54.7%) and 1717−1G/A/2143delT in 2/42. The clinical picture was dominated by respiratory symptoms (16/42) and/or body mass deficiency (9/42). In 24/42 infants elevated acid steatocrit in faeces was detected. No statistically significant differences were observed between clinical symptoms, the birth weight, the birth Apgar score and mutation of CFTR gene. Increased aminotransferase activity was observed in 10/42 infants, whereas GGTP in 15/42. In 7/42 children the abdominal ultrasound revealed hepatic abnormalities, most often in the form of liver enlargement and/or increased echogenicity. Conclusion: Features of liver damage and/or cholestasis were observed even in the youngest patients with diagnosed cystic fibrosis. Mutation delF508 was the most common abnormality of the genotype, which could have some impact on the manifestation of hepatic abnormalities.
